ARS Pharmaceuticals, Inc. (SPRY) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for ARS Pharmaceuticals, Inc. (SPRY): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 29/100 — a percentile rank of ARS Pharmaceuticals, Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.
| Market cap | $520.1M |
| P / S | 4.5× |
| EV / EBITDA | -3.2× |
| Gross margin | 71.4% |
| Operating margin | -185.0% |
| Net margin | -184.0% |
| Return on equity | -1719.7% |
| ROIC | -122.9% |
| Revenue growth | 4.1% |
| Debt / equity | 13.7× |
| Dividend yield | 0.0% |
Is ARS Pharmaceuticals, Inc. overvalued? P/S looks fair vs its 5-year range; P/B looks fair vs its 5-year range.
Independent of the events above — derived from ARS Pharmaceuticals, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact